4D Molecular Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-17.0%projected annual EPS growth
Analyst Coverage
9analysts covering
FY EPS (est.)
-$3.93next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents and Marketable Securities Quarterly457.6MTarget: Sufficient to fund planned operations into H2 2028
4FRONT-1 Phase 3 Wet AMD Trial Enrollment Quarterly500.0Target: Completed enrollment (over 500 patients randomized)
Collaboration and License Revenue Quarterly3MTarget: Driven by clinical trial cost sharing and reimbursement from Otsuka
Watch Items
- 4FRONT-1 Topline Clinical Data ReadoutTrigger: First half of 2027 (H1 2027)Action: Evaluate non-inferiority in mean change from baseline in best-corrected visual acuity (BCVA) at 52 weeks compared to aflibercept.
- 4FRONT-2 Global Phase 3 Wet AMD Trial Enrollment CompletionTrigger: Second half of 2026 (H2 2026)Action: Monitor ex-U.S. site activation and patient screening acceleration across Europe and Asia-Pacific.
- 4D-150 DME Global Phase 3 Trial InitiationTrigger: Third quarter of 2026 (Q3 2026)Action: Review final Phase 3 trial design in mid-2026 and track first patient dosing.
- 4D-710 Cystic Fibrosis Program UpdateTrigger: Second half of 2026 (H2 2026)Action: Assess Phase 2 clinical data and development progress funded by the Cystic Fibrosis Foundation.
Research as of 20 Jun 2026